Hayes K A, Wilkinson J G, Frick R, Francke S, Mathes L E
Department of Veterinary Pathobiology, Ohio State University, Columbus 43210, USA.
J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Jun 1;9(2):114-22.
Prophylactic zidovudine (ZDV) therapy in feline immunodeficiency virus (FIV) inoculated cats was evaluated for 12 months postinfection (pi) and 11 months post drug treatment. Plasma FIV antigenemia was prevented in six of six ZDV-treated and none of six untreated cats during the initial phase of infection. The present study is a continuation of that earlier work. CD4 lymphocyte numbers from ZDV-treated cats were higher than in the untreated cats. CD8 lymphocytes numbers were maintained within control limits in the ZDV-treated cats, while they declined in the untreated cats. Anti-FIV antibody titers were comparable between the ZDV-treated and the untreated cats. Histologically, lymphoid tissues for the untreated and ZDV-treated cats were unremarkable and similar to those of the uninfected control cats. Low-level FIV antigen was detected by enzyme-linked immunosorbent assay in thymus or lymph node homogenates from 3 of 11 cats tested. Polymerase chain reaction analysis showed FIV DNA in blood, lymph node, bone marrow, spleen, thymus, and brain from FIV-inoculated cats irrespective of ZDV treatment. Therefore, while prophylactic ZDV treatment prevented detectable plasma antigenemia and FIV-induced CD8 lymphocyte decline, it did not slow infection of tissues and blood cells of FIV-inoculated cats.
